The latest price target for Icecure Medical (NASDAQ:ICCM) was reported by HC Wainwright & Co. on November 27, 2024. The analyst firm set a price target for $2.50 expecting ICCM to rise to within 12 months (a possible 125.23% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Icecure Medical (NASDAQ:ICCM) was provided by HC Wainwright & Co., and Icecure Medical reiterated their buy rating.

There is no last upgrade for Icecure Medical

There is no last downgrade for Icecure Medical.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Icecure Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Icecure Medical was filed on November 27, 2024 so you should expect the next rating to be made available sometime around November 27, 2025.

While ratings are subjective and will change, the latest Icecure Medical (ICCM) rating was a reiterated with a price target of $2.50 to $2.50. The current price Icecure Medical (ICCM) is trading at is $1.11, which is out of the analyst’s predicted range.